FLT3 and acute myeloid leukemia: FLT3-ITD could stratify the outcomes of NK-AML patients (24% ± 19% vs. 54.4% ± 10.5%, P = 0.035; 0% vs. 51.7% ± 8.4%, P = 0.004; 0% vs. 47.9% ± 7.6%, P = 0.000).